%0 Journal Article
%T Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan
%A Bor-Sheng Ko
%A Cheng-Shyong Chang
%A Ming-Chih Chang
%A Sheng-Fung Lin
%A Su-Peng Yeh
%A Te-Kau Chang
%A Tsai-Yun Chen
%A Tzeon-Jye Chiou
%A Wei-Shou Hwang
%A Yeu-Chin Chen
%A Yin-Che Lu
%J Hematology
%D 2019
%R https://doi.org/10.1080/16078454.2018.1557860
%X ABSTRACT Objective: Patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemia require chronic blood transfusions which can lead to iron overload and subsequent excess iron-mediated complications. Intensive iron chelation with deferasirox could remove excess iron and can alleviate these events; however, the long-term safety and efficacy in Chinese population are not clearly characterized. This study examined the long-term efficacy and safety of deferasirox in a real-world setting in Taiwan. Methods: This observational, non-interventional, single-arm, multi-center, phase IV study was designed to collect the safety and clinical information about patients who were treated with deferasirox according to investigator¡¯s judgment and in accordance with the general clinical practice. Results: From 2009 to 2011, patients with MDS (N£¿=£¿38), AA (N£¿=£¿23), and other rare anemias (N£¿=£¿18) were enrolled. The mean deferasirox exposure was 17.7£¿¡À£¿4.02£¿mg/kg/day. The most common drug-related AEs were skin disorders (32.9%) and gastrointestinal disorders (30.4%), while grade 3¨C4 AEs were rare (5.1%). In the overall patient population, deferasirox effectively decreased serum ferritin levels at 1 year (P£¿=£¿0.0154) and 3 years (P£¿=£¿0.0424) from the baseline. Upon the use of deferasirox, 32.9% patients showed erythroid response and 16.7% patients had platelet response. Conclusions: For patients with MDS, AA, and other rare anemias, the AEs observed in this 3-year surveillance study with deferasirox were mostly mild or moderate. In addition, the hematological response rate was higher than that in the EPIC study, which primarily enrolled Caucasian patients
%U https://www.tandfonline.com/doi/full/10.1080/16078454.2018.1557860